Study guide

17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

Key Takeaways Explain This Topic AI

ACEP's 2023 severe agitation policy favors droperidol or an atypical antipsychotic combined with midazolam, and advises against midazolam alone when a single agent is used.

Serotonin syndrome develops within hours and features clonus and hyperreflexia; it is treated with benzodiazepines and cyproheptadine 12 mg, then 2 mg every 2 hours while symptoms continue.

Neuroleptic malignant syndrome develops over days with lead-pipe rigidity and slowed reflexes; it is treated by stopping the drug, cooling, benzodiazepines, and dantrolene or bromocriptine for severe cases.

EXTRIP recommends dialysis for lithium toxicity when the level exceeds 4.0 mEq/L with impaired kidney function, or with reduced consciousness, seizures or life-threatening dysrhythmias at any level.

Clozapine missed for 2 or more days must be restarted at 12.5 mg once or twice daily and re-titrated, even though FDA ended the clozapine REMS in 2025.

Last updated: October 2026

17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

Note

Exam scope: 2025 outline subtopic 2B10 (Pharmacotherapy for Psychiatric Emergencies) with related toxicology from 2B13. Alcohol and sedative withdrawal are covered in Section 8.4, and tricyclic and anticholinergic toxicity in Section 9.1.

  • Severe Agitation
  • Medical Causes First

Agitation is a symptom, not a diagnosis. Check glucose, oxygenation and vital signs early and consider hypoglycemia, hypoxia, intoxication, withdrawal, CNS infection, head injury, thyroid storm and delirium. ACEP no longer recognizes the term "excited delirium"; describe the presentation clinically instead, such as hyperactive delirium with severe agitation.

Verbal de-escalation comes first. Offer oral medication to a patient who will cooperate:

  • Olanzapine orally disintegrating tablets 10 mg
  • Risperidone 2 mg (liquid or orally disintegrating)
  • Lorazepam 2 mg
  • Sublingual dexmedetomidine film (approved in 2022 for agitation in schizophrenia or bipolar disorder)
  • Parenteral Treatment (ACEP Clinical Policy, 2023)

Strength Recommendation

Level B For faster and more effective control, use droperidol plus midazolam or an atypical antipsychotic plus midazolam

Level B If only one drug can be given, use droperidol or an atypical antipsychotic rather than midazolam alone, because midazolam alone has more adverse effects

Level B Haloperidol alone, or with lorazepam, is also effective

Level C (consensus) When the safety of the patient, bystanders or staff is threatened, consider ketamine IV or IM

Drug Typical adult IM dose Notes

Droperidol 5 mg (2.5 to 10 mg) Boxed warning for QT prolongation (2001); ED studies show dysrhythmias are rare at these doses

Haloperidol 5 mg, often with lorazepam 2 mg Dystonia (prevented or treated with diphenhydramine or benztropine), QT prolongation

Olanzapine 10 mg Do not combine IM olanzapine with parenteral benzodiazepines , because of reports of fatal cardiorespiratory depression

  • Ziprasidone 10 to 20 mg (maximum 40 mg/day) QT prolongation; slower onset
  • Midazolam 5 mg Fast IM onset; respiratory depression, especially with alcohol

Ketamine 4 to 5 mg/kg Fastest control; vomiting, laryngospasm, emergence reactions, and higher intubation rates in some prehospital series

Monitor every chemically restrained patient continuously, with capnography when deeply sedated. Avoid prone restraint , which has been linked to deaths, and remove restraints as soon as possible.

Drug-Induced Hyperthermic Syndromes

Feature Serotonin syndrome Neuroleptic malignant syndrome (NMS) Anticholinergic toxicity Malignant hyperthermia

Trigger Serotonergic drugs, often a new agent or dose increase Dopamine antagonists, or stopping dopaminergic drugs Antimuscarinic drugs Volatile anesthetics, succinylcholine

Onset Hours (usually within 24) Days to weeks Hours Minutes to hours during anesthesia

Neuromuscular Clonus and hyperreflexia , legs more than arms Lead-pipe rigidity, slowed reflexes Normal Rigidity

  • Skin Diaphoretic Diaphoretic Dry Mottled, diaphoretic
  • Pupils Dilated Normal Dilated Normal
  • Bowel sounds Increased, diarrhea Normal or decreased Absent Normal

Key treatment Benzodiazepines, cyproheptadine Stop the drug , cooling, benzodiazepines, dantrolene or bromocriptine Physostigmine in selected patients (Section 9.1) Dantrolene 2.5 mg/kg IV

Serotonin Syndrome

Hunter criteria (in a patient taking a serotonergic drug), any one of:

  • Spontaneous clonus
  • Inducible clonus with agitation or diaphoresis
  • Ocular clonus with agitation or diaphoresis
  • Tremor with hyperreflexia
  • Hypertonia with temperature above 38 °C and ocular or inducible clonus

Common culprits: SSRIs, SNRIs and MAO inhibitors combined with linezolid, methylene blue, tramadol, meperidine, fentanyl, dextromethorphan , triptans (low risk) or MDMA.

Treatment:

Stop all serotonergic drugs and give supportive care.

Give benzodiazepines for agitation and muscle activity.

Give cyproheptadine 12 mg orally or by tube, then 2 mg every 2 hours while symptoms continue. Maintenance is 8 mg every 6 hours (maximum 32 mg/day). It is available only orally and sedates.

For temperature above about 41 °C, give sedation, non-depolarizing paralysis and intubation . Antipyretics do not work because the heat comes from muscle activity.

Avoid physical restraints, which increase muscle activity and lactic acidosis.

Neuroleptic Malignant Syndrome

Stop the antipsychotic (or restart a dopaminergic drug that was stopped abruptly, such as levodopa).

Cool actively, give IV fluids for rhabdomyolysis, and give benzodiazepines.

For severe or progressive cases:

Dantrolene 1 to 2.5 mg/kg IV, repeated as needed (up to about 10 mg/kg/day) to relax muscle.

Bromocriptine 2.5 mg by mouth or tube every 8 hours, titrated, to restore dopamine activity.

Amantadine is an alternative, and electroconvulsive therapy is used for refractory cases.

Wait at least 2 weeks after recovery before carefully restarting an antipsychotic, using a lower-potency agent at a low dose.

Lithium Toxicity

The therapeutic range is about 0.6 to 1.2 mEq/L . Lithium is cleared by the kidneys and handled like sodium.

Type Features

Acute (no prior use) GI symptoms first; neurotoxicity appears later as lithium enters the brain; a high level can be fairly well tolerated at first

Chronic (dehydration, kidney injury, interacting drugs) Neurotoxicity at modestly raised levels : tremor, confusion, hyperreflexia, ataxia, seizures

Acute-on-chronic Both, often severe

Precipitants of chronic toxicity: volume depletion, NSAIDs, ACE inhibitors and ARBs, thiazide diuretics, and kidney injury.

Treatment:

IV normal saline to restore volume and lithium clearance. Watch sodium, because lithium-induced nephrogenic diabetes insipidus can cause hypernatremia.

No activated charcoal , which does not bind lithium. Use whole bowel irrigation for large sustained-release ingestions (Section 8.1).

Stop interacting drugs.

Hemodialysis (EXTRIP 2015):

Recommended when the level is above 4.0 mEq/L with impaired kidney function , or with decreased consciousness, seizures or life-threatening dysrhythmias at any level .

Suggested when the level is above 5.0 mEq/L, there is significant confusion, or the expected time to reach a level below 1.0 mEq/L with optimal care is more than 36 hours.

Recheck the level after dialysis, because lithium redistributes from tissue and levels rebound.

Some patients have lasting cerebellar damage (the syndrome of irreversible lithium-effectuated neurotoxicity, SILENT).

Dangerous Features of Psychotropic Overdoses

Agent Key toxicity Pharmacist pearl

Bupropion Seizures (can be delayed with extended-release forms), tachycardia, QRS widening Observe extended-release ingestions for at least 24 hours

  • Venlafaxine Seizures, sodium-channel cardiotoxicity, serotonin toxicity More toxic in overdose than SSRIs
  • Citalopram, escitalopram QTc prolongation that can be delayed for hours, seizures Use serial ECGs
  • Quetiapine Sedation, hypotension (alpha blockade), tachycardia Often intubated for airway protection

Tricyclic antidepressants Sodium-channel block, seizures, anticholinergic effects Sodium bicarbonate for QRS of 100 ms or more (Section 9.1)

MAO inhibitors Delayed hypertensive crisis followed by hypotension; serotonin syndrome Admit for at least 24 hours of monitoring

Patients Boarding With Psychiatric Illness

Continue home psychiatric medications. Omissions cause withdrawal, relapse and longer stays. Confirm doses with the pharmacy or clinic, and record when long-acting injectable antipsychotics are due.

Clozapine:

If 2 or more days have been missed, restart at 12.5 mg once or twice daily and re-titrate. Restarting at the full dose risks hypotension, bradycardia, syncope and seizures.

Clozapine also causes constipation and ileus, myocarditis, seizures and neutropenia.

Stopping smoking raises clozapine levels , because tobacco smoke induces CYP1A2. This matters in smoke-free EDs.

FDA ended the clozapine REMS program in 2025, but it still recommends monitoring the absolute neutrophil count as described in the labeling.

Suicide risk: screen with a validated tool. At discharge, limit the quantity of dangerous medications and counsel on restricting access to lethal means, including stored medications and firearms. The Joint Commission's 2026 National Performance Goals include a goal on reducing suicide risk.